Could ICER Outreach To US FDA Lead To Better Cost Effectiveness Analyses?
Executive Summary
To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.
You may also be interested in...
ICER Enhanced Patient Engagement Program Will Be Led By Former Biopharma Exec
Yvette Venable has more than 20 years’ experience in patient advocacy, heath policy and biopharma communications.
Patient-Focused Drug Development: US FDA’s Guidance Development Effort Passes The Mid-Point
Agency has issued two of four methodological draft guidances required under 21st Century Cures Act and convened workshops on the two documents still to come; industry, patient groups applaud FDA’s initiative but point to gaps in the guidance series, particularly around interactions with the agency on patient experience data and approaches to collecting patient preference information.
ICER Will Assess Real World Evidence On Accelerated Approvals After Two Years
Process will incorporate real world evidence into future cost effectiveness updates of already reviewed drugs to supplement the information available prior to launch.